MedTech News
.................... by Andrew Celentano
Butterfly Medical secures EU MDR certification for BPH implant
The European certification follows the conclusion of a pivotal clinical study evaluating 244 patients.
Molecular glue degraders show early promise in reducing Alzheimer’s-linked brain plaques
A research team led by Indiana University School of Medicine scientists has discovered a new method for reducing the formation of amyloid plaques, which disrupt brain function in all aging adults but are particularly prevalent in patients with Alzheimer’s disease and related dementias.
FDA approves Providence Medical’s CORUS PCSS 3D-T spinal device
CORUS incorporates integrated screw fixation as a nonsegmental posterior instrumentation tool.
A gut microbe makes a fatty acid that cuts artery plaque in half in mice
A common gut bacterium produces a molecule that slows cholesterol production in the liver. When researchers gave the molecule to mice prone to artery disease, the animals developed roughly half as much fatty plaque as untreated controls.
FDA APPROVES GORE® VIABAHN® VBX BALLOON EXPANDABLE ENDOPROSTHESIS FOR EXPANDED USE IN FEVAR AND BEVAR
FLAGSTAFF, Ariz., Oct. 14, 2026 /PRNewswire/ — W. L. Gore & Associates’ medical business (Gore) today announced U.S. Food and Drug Administration approval of an expanded indication for the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) for use in fenestrated and branched endovascular aortic repair (FEVAR and BEVAR).
Maverix Medical Expands the Narwhal™ Cryo Portfolio with FDA Clearance of the Narwhal Pro
MENLO PARK, Calif., Oct. 14, 2026/PRNewswire/ — Maverix Medical, a company focused on revolutionizing the diagnosis and treatment of lung cancer, has augmented its console-free cryoprobe portfolio. Today the company announced that the U.S. Food and Drug Administration granted 510(k) clearance on September 2, 2026, to the Maverix Narwhal™ Pro Cryo System, the second of two flexible cryoprobes built on the same cartridge-powered architecture.
Florida Cancer Specialists & Research Institute Contributes to Two Significant FDA Approvals Advancing Breast and Pancreatic Cancer Care
FORT MYERS, Fla., Oct. 14, 2026 /PRNewswire/ — Florida Cancer Specialists & Research Institute, LLC (FCS) is celebrating its pivotal role in the development of two recently approved targeted therapies that expand treatment options for patients with advanced breast and pancreatic cancers, underscoring the FCS’s longstanding commitment to advancing oncology research and expanding access to clinical trials.
Trial Demonstrates Feasibility of At-Home Subcutaneous Diuretic Therapy for Heart Failure-Associated Edema
BURLINGTON, Mass., Oct. 14, 2026 /PRNewswire/ — SQ Innovation today announced that results of the SUBCUT HF II trial of its product Lasix® ONYU have been published in the Journal of the American College of Cardiology (JACC)1, one of the leading peer-reviewed journals in cardiovascular medicine.